Membranoproliferative GN and C3 glomerulopathy
MPGN/C3G · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A pattern of glomerular injury with mesangial/capillary wall proliferation, now classified by immunofluorescence into immune-complex-mediated MPGN and complement-mediated C3 glomerulopathy. Work-up targets infection, autoimmunity, paraproteins and alternative complement pathway dysregulation.
Red flags
- Rapidly progressive renal failure (crescents on biopsy)
- Nephrotic syndrome with thrombosis
- Underlying monoclonal gammopathy
- Cryoglobulinaemia with systemic vasculitis
- Recurrent disease in a transplant
Assessment
Differential diagnosis
- Immune-complex MPGN (hepatitis C/B, cryoglobulinaemia, autoimmune)
- C3 glomerulopathy (C3GN, dense deposit disease)
- Monoclonal gammopathy-associated MPGN
- Post-infectious/infection-related GN
- Lupus nephritis
- Thrombotic microangiopathy (overlapping pattern)
Investigations
- Complement C3 and C4 (low C3 with normal C4 suggests alternative pathway/C3G)
- Hepatitis B/C serology, cryoglobulins, ANA/dsDNA
- Serum/urine electrophoresis and free light chains (paraprotein)
- Complement functional assays (C3 nephritic factor, factor H/I) in C3G
- Urinalysis/ACR/PCR and renal function
- Renal biopsy with immunofluorescence and electron microscopy (defines subtype)
Management
- Recognise the nephritic/nephrotic mixed picture and arrange renal biopsy to define the MPGN pattern and immunofluorescence subtype
- Check complement: low C3 with normal C4 points to alternative-pathway/C3 glomerulopathy
- Screen exhaustively for secondary causes: hepatitis B/C, cryoglobulins, autoimmune disease and monoclonal gammopathy
- Treat the underlying cause when identified (e.g. antiviral therapy for hepatitis C, treat the clone in MGRS-associated disease)
- Provide supportive nephroprotection: RAAS blockade, BP control and proteinuria reduction
- For idiopathic immune-complex MPGN with significant disease, consider immunosuppression (steroids +/- other agents) per severity
- For C3 glomerulopathy, pursue complement work-up (nephritic factors, genetic/factor assays) via specialist services
- Consider complement-directed therapy (e.g. eculizumab) in selected rapidly progressive C3G at specialist centres
- Manage nephrotic complications (oedema, thrombosis risk, hyperlipidaemia)
- Monitor renal function, proteinuria and complement response
- Plan for transplantation awareness — C3G and MPGN frequently recur in grafts
- Provide long-term nephrology follow-up and genetic counselling in complement-mediated disease
Drugs & doses
Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily (nephroprotection)
Prednisolone 1 mg/kg/day PO (selected idiopathic immune-complex MPGN), tapered
Mycophenolate mofetil 500-1000 mg PO twice daily (steroid-sparing in selected cases)
Direct-acting antivirals for hepatitis C-associated cryoglobulinaemic MPGN (per hepatology)
Eculizumab (specialist, dosed per protocol) for selected rapidly progressive C3 glomerulopathy
Atorvastatin 20-80 mg PO daily (nephrotic dyslipidaemia)
Disposition
Nephrology management with renal biopsy; specialist complement/glomerular service for C3 glomerulopathy. Haematology for paraprotein-associated disease. Transplant counselling on recurrence.
Complications & pitfalls
- Progression to end-stage kidney disease
- Nephrotic complications (thrombosis, infection, hyperlipidaemia)
- Disease recurrence after transplantation
- Complement dysregulation-driven relapse
- Treatment-related immunosuppression toxicity
Exam pearls
- Immunofluorescence reclassifies MPGN into immune-complex vs C3 glomerulopathy — this drives work-up
- Low C3 with normal C4 flags the alternative complement pathway (C3G)
- Always exclude hepatitis C, cryoglobulins and a monoclonal protein
- C3 glomerulopathy and MPGN commonly recur after transplantation
- Treat the cause (virus, clone) where one is found rather than immunosuppressing blindly
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.